What's in Actavis Inc.'s pipeline?

Actavis Inc. has 29 drugs in our index: 4 marketed, 0 filed, 21 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Actavis Inc.'s portfolio?

Top competitors by shared drug class: Padagis LLC, Galderma R&D, LEO Pharma, GlaxoSmithKline, Stiefel, a GSK Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/actavis-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Actavis Inc. — Portfolio Competitive Intelligence Brief

Actavis Inc. pipeline: 4 marketed, 0 filed, 21 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 21 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Zyclara®	Zyclara®	marketed	Toll-like receptor agonist	TLR7, TLR8	Dermatology/Oncology
Clindamycin/benzoyl peroxide gel	Clindamycin/benzoyl peroxide gel	marketed	Antibiotic/keratolytic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)	Dermatology
Finacea	Finacea	marketed		3-oxo-5-alpha-steroid 4-dehydrogenase 2	Dermatology
KADIAN	KADIAN	marketed			Pain
Generic Ivermectin Lotion 0.5%	Generic Ivermectin Lotion 0.5%	phase 3	Antiparasitic agent	Glutamate-gated chloride channels	Dermatology / Parasitic Infections
Test-Brinzolamide 1% Ophthalmic suspension	Test-Brinzolamide 1% Ophthalmic suspension	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II	Ophthalmology
clindamycin phosphate vaginal cream 2%	clindamycin phosphate vaginal cream 2%	phase 3	Lincosamide antibiotic	Bacterial 50S ribosomal subunit	Infectious Disease / Gynecology
Placebo/Vehicle cream	Placebo/Vehicle cream	phase 3
Generic Budesonide/Formoterol Fumarate Dihydrate	Generic Budesonide/Formoterol Fumarate Dihydrate	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
Generic Azelaic Acid Foam	Generic Azelaic Acid Foam	phase 3	Topical antimicrobial and anti-inflammatory agent		Dermatology
Carac® (Fluorouracil) Cream	Carac® (Fluorouracil) Cream	phase 3	Antimetabolite; Pyrimidine analog	Thymidylate synthase; DNA and RNA synthesis	Oncology; Dermatology
Reference-Brinzolamide 1% Ophthalmic suspension	Reference-Brinzolamide 1% Ophthalmic suspension	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II	Ophthalmology

Therapeutic area mix

Dermatology · 9
Ophthalmology · 3
Dermatology/Oncology · 2
Oncology; Dermatology · 2
Gynecology / Menopause · 2
Respiratory/Pulmonology · 1
Dermatology / Parasitic Infections · 1
Gynecology · 1
Infectious Disease / Gynecology · 1
Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Padagis LLC · 4 shared drug classes
Galderma R&D · 4 shared drug classes
LEO Pharma · 4 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Stiefel, a GSK Company · 3 shared drug classes
EMS · 2 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
Bayer · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Actavis Inc.:

Cite this brief

Drug Landscape (2026). Actavis Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/actavis-inc. Accessed 2026-05-13.